Key facts
- It has raised $20.7M across 2 recorded rounds; the latest was Early Stage VC ($16.3M) in Mar 2024.
- Notable investors include US National Science Foundation, MedTech Innovator, National Institutes of Health, CONNECT(San Diego), Johnson & Johnson JJDC — 14 tracked in total.
- Tempo Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Mar 2024 ($16.3M sold to 26 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Tempo Therapeutics
Funding rounds
2 roundsAbout Tempo Therapeutics
Operator of a life science company intended to harness the power of immunomodulation and material science to transform the landscape of medical technology. The company's hydrogel uses cell-free synthetic materials that use geometric technology to unlock the body's regenerative capacity and control inflammation, enabling patients to achieve accelerated healing rates, reduced chronic tissue inflammation, and increased regenerative healing.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2013
- Employees
- 15
- Website
- tempothera.com/
- Ownership
- Privately Held (backing)
Tempo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tempo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tempo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.